About Us

Cell Therapies to Restore Liver Function & Regenerate the Liver

Ambys is advancing an entirely new cell therapy approach to treat severe liver disease so that the millions of people affected will one day have treatments that can improve or save their lives.

Liver diseases are among the most challenging and underserved areas of modern medicine. Despite some progress, most liver diseases – both chronic and acute – are not effectively addressed by currently available treatments.

For patients with severe liver diseases, liver transplant is the only option. Those fortunate enough to receive a donor liver face a difficult operation, months of recovery, and a lifetime of immuno-suppressive drugs. More than 60,000 cirrhosis patients die annually in the U.S. – this number is expected to continue to rise.


A Revolutionary Approach

We are pioneering the novel application of cell therapies to restore and reverse liver disease progression. Until now, current therapeutic approaches have been limited in their ability to successfully treat severe liver diseases due to the nature of the liver. This requires a completely transformational, cutting-edge approach to how medicines are conceived and developed. We believe our liver cell therapies have the potential to overcome these treatment challenges and offer a breakthrough treatment advance for patients.

Our Lead Programs

Our lead programs, including AMI-918, an “off the shelf” hepatocyte replacement cell therapy, harness the natural regenerative properties of the liver and target a spectrum of severe acute and chronic liver diseases to restore normal liver function.

Leadership Team

John Choi headshot
John Choi
VP, Regulatory Affairs
Corinne Foo-Atkins, MBBS, MBA, MSc
Chief Strategy Officer
Markus Grompe, M.D.
Co-Founder & Chief Scientific Officer
photo of Stanley
Stanley Hollenbach, J.D.
SVP, Pharmacology
John McKeon headshot
John McKeon
VP, Finance
Ronald Park, M.D., M.B.A.
Chief Executive Officer
Board Member
Deidre Roniger
SVP Corporate Development
Samira Shaikhly
Chief Human Resources Officer
Alan Smith, Ph.D.
Chief Technology Officer
Jennifer Cook
Independent Board Director
Nenad Grmusa
SVP Head of R&D Strategy and External Innovation and CFO R&D, Takeda
Charles Homcy, M.D.
Third Rock Ventures
Board Member
Asit Parikh, M.D., Ph.D.
Independent Board Director
Ronald Park, M.D., M.B.A.
Chief Executive Officer
Jeff Tong, Ph.D.
Third Rock Ventures
Chairman of the Board
Chinweike Ukomadu, M.D., Ph.D.
SVP and Head, GI TA at Takeda
Board Observer
Martin Burke, M.D., Ph.D.
University of Illinois at Urbana-Champaign
Juan Carlos Izpisua Belmonte, Ph.D.
Salk Institute
Markus Grompe, M.D.
Oregon Health and Sciences University
Holger Willenbring, M.D., Ph.D.
University of California, San Francisco
Daniel P. Anderson, Ph.D.
Massachusetts Institute of Technology
Marble Center for Cancer Nanomedicine
Broad Institute of MIT and Harvard
Ragon Institute at MGH, MIT and Harvard
Michael Holmes, Ph.D.
Tessera Therapeutics
Brendan Lee, M.D., Ph.D.
Baylor College of Medicine
Texas Medical Center Bone Disease Program of Texas
Yury Popov, M.D., Ph.D.
Harvard Medical School
Beth Israel Deaconess Medical Center
David Russell, M.D., Ph.D.
University of Washington
Holger Willenbring, M.D., Ph.D.
University of California San Francisco
Eli and Edythe Broad Center of Regeneration Medicine and Stem Cell Research
Robert S. Brown Jr., M.D., MPH
Weill Cornell Medicine
Raymond Chung, M.D.
Massachusetts General Hospital
Harvard Medical School
Steven D. Colquhoun, M.D.
Cedars Sinai Medical Center
Robert Fisher, M.D.
Beth Israel Deaconess Medical Center
Harvard Medical School
Paul Kwo, M.D.
Stanford University
Scott Naugler, M.D.
Oregon Health and Science University
Stephen Strom, Ph.D.
Karolinska Institutet